586 results on '"Ferrero, Dario"'
Search Results
2. Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study
3. Query in linguaggio naturale per il dominio della dieta mediterranea
4. Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant
5. Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial
6. Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience
7. Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7
8. Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML
9. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
10. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline
11. Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission
12. Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax
13. PB1864: IMPROVED LONG-TERM SURVIVAL OF ELDERLY ADULTS WITH AML RECEIVING INTENSIVE INDUCTION THERAPY FOLLOWED BY EITHER ALLOGENEIC STEM CELL TRANSPLANT OR MAINTENANCE DIFFERENTIATIVE THERAPY
14. P678: EARLY WARNING RESPONSES IN CML PATIENTS: A REAL-LIFE TURIN EXPERIENCE
15. PB2057: THE COMBINATION OF ANTI-COMPLEMENT THERAPY AND CYCLOSPORINE +/- ELTROMBOPAG IN PNH IS EFFECTIVE AND SAFE: A REAL-LIFE OBSERVATIONAL STUDY.
16. Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors
17. Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients
18. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
19. Modern Measurements: Fundamentals and Applications
20. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series
21. Proceedings of the Eighth Italian Conference on Computational Linguistics CliC-it 2021
22. Query in linguaggio naturale per il dominio della dieta mediterranea
23. Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
24. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival
25. PB2670: EQOL‐MDS TRIAL: PATIENT‐REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
26. Lack of efficacy of convalescent plasma in COVID‐19 patients with concomitant hematological malignancies: An Italian retrospective study
27. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience
28. Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment
29. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party
30. Real-World Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anaemia Due to Lower-Risk Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS), Who Had an Unsatisfactory Response to or are Ineligible for Erythropoiesis Stimulating Agents: A Retrospective, Multicenter, Cohort Study
31. Hematopoietic Stem Cells (HSC) and Granulocyte Macrophage Progenitors (GMP) are the Oxidative Stress Targets in Low/Intermediate-1 Risk Myelodysplastic Syndromes
32. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents
33. Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved?
34. Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant
35. Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021
36. Growth- and Tumor-Promoting Effects of Deregulated BCL2 in Human B-Lymphoblastoid Cells
37. Antigenically Distinct Subpopulations of Myeloid Progenitor Cells (CFU-GM) in Human Peripheral Blood and Marrow
38. Transformation and Plasmacytoid Differentiation of EBV-Infected Human B Lymphoblasts by ras Oncogenes
39. Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study
40. Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06
41. Myd88l265p detection in igm monoclonal gammopathies: Methodological considerations for routine implementation
42. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
43. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs
44. MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation
45. Long-term lymphoma survivors following high-dose chemotherapy and autograft: Evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir
46. Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia
47. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice
48. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: A retrospective study on 91 unselected patients
49. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival
50. Azacitidine for the treatment of patients with acute myeloid leukemia: Report of 82 patients enrolled in an Italian compassionate program
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.